Dual-field researcher: real-world obesity pharmacotherapy and privacy-preserving synthetic data for biomedical AI
2
papers here
2
reviewed by Evolve
0
first-author
0
corresponding
—
works · OpenAlex
—
h-index · OpenAlex
Bibliometric figures come from OpenAlex (2026-10-02) and cover the author's entire public record, not just the papers listed here. Reproducibility signal comes from Evolve's own reviews.
Research profile
Output—
Insufficient data: no publication-count, venue-tier, or authorship-position metrics are available for this name-resolved profile yet. This axis would measure total scholarly output across the full publication record, beyond the two reviewed 2026 preprints.
Impact—
Insufficient data: citation counts, h-index, and uptake metrics are not yet available. This axis would measure how widely the two 2026 preprints and any prior work are cited and adopted across the obesity-medicine and statistical-privacy communities.
Focus0/100
Scores 0 because the record splits perfectly: the field distribution is 50% clinical endocrinology (obesity medicine) and 50% computational biology / statistical privacy, with no dominant field. The two reviewed 2026 outputs sit in disconnected literatures — a medRxiv microdose tirzepatide study and a bioRxiv synthetic-data paper — so the profile reads as deliberately cross-disciplinary rather than narrowly specialized.
Collaboration58/100
Scores 58, computed from 17 distinct coauthors across the reviewed record. A recurring core of 12 collaborators spans both fields — Hastings, J., He, Z., Park, S. J., Pulgrossi, R. C., Butler, R. R., Weber, A., Tian, L., Zhang, X., Wang, J., Sha, S., Mormino, E. C., and Wyss-Coray, T. — indicating team-based preprint work rather than solo authorship.
Activity—
Insufficient data: no time-indexed publication frequency is available, so research tempo cannot be scored. This axis would measure publication cadence and ongoing activity in recent years; both reviewed papers are dated 2026, which alone cannot establish a trend.
Reproducibility38/100
Scores 38, the mean across 2 scored papers. The medRxiv microdose tirzepatide study rates low readiness — an uncontrolled vendor-data design with selection bias — while the SPHERE paper reaches medium readiness: its synthetic-data claims are promising, but algorithm secrecy and a non-standard privacy framework block independent verification.
Research summary
Lee, J. is a name-resolved profile built from public bibliographic data, with no institution, country, or ORCID attached. The available record covers two 2026 preprints reviewed in the Evolve catalog and splits evenly between fields: 50% clinical endocrinology (obesity medicine) and 50% computational biology / statistical privacy — an unusual dual footprint. On the clinical side, Lee served as last author on a medRxiv study of microdose tirzepatide (1–2 mg weekly), reporting 2.2–6.1% weight loss in real-world telehealth patients; Evolve characterizes it as a transparent but hypothesis-generating vendor-data study, uncontrolled and selection-biased, with low reproducibility readiness. On the computational side, Lee contributed as a middle author to the SPHERE paper on bioRxiv, which claims exact-moment synthetic twins of sensitive datasets with strong privacy and AI-agent utility, drawing on resources such as UK Biobank — though algorithm secrecy and a non-standard privacy framework limit verification, and readiness is rated medium. The collaboration footprint spans 17 distinct coauthors (collaboration score 58) with a recurring core of 12 collaborators, while the even field split yields a focus score of 0 and a reproducibility mean of 38 across the two scored papers. Output, impact, and activity metrics are not yet available.
Collaboration pattern
Lee's reviewed work is team-produced: 17 distinct coauthors appear across the two 2026 preprints, with a recurring core of 12 collaborators — including Hastings, J., He, Z., Park, S. J., Weber, A., Tian, L., Mormino, E. C., and Wyss-Coray, T. The roster suggests two clusters: a clinical/telehealth group behind the tirzepatide study and a computational group behind SPHERE. Lee is positioned last author on the clinical paper and mid-list on the computational one, and is corresponding author on neither.
Research keywords
Highlights
Microdose tirzepatide: real-world weight-loss signal at 1–2 mg weekly
SPHERE: synthetic twins of sensitive data in the AI era
Timeline
- 2026Served as last author on a medRxiv real-world study of microdose tirzepatide (1–2 mg weekly), reporting 2.2–6.1% weight loss.
- 2026Co-authored the SPHERE paper on bioRxiv (middle author), claiming privacy-preserving synthetic twins with utility for AI agents.
- 2026Both preprints entered the Evolve review catalog, establishing a dual-field profile spanning obesity pharmacotherapy and statistical privacy.
Papers in the Evolve catalog
Frequent co-authors
About this profile
This profile is AI-structured by Evolve.Pub from public bibliographic data (OpenAlex) and Evolve's own paper reviews. It is not written or endorsed by the researcher unless the profile is claimed. Radar dimensions are computed from real bibliometrics with fixed formulas — raw figures are shown alongside; missing dimensions mean insufficient data, never zero. Errors? Claim the profile to correct or hide it.
- Bibliometrics and radar scores come from OpenAlex-sourced public data only; no institution, country, or ORCID is attached to this profile.
- "Lee, J." is a common name: the profile is name-resolved from public bibliographic data and could merge or split distinct individuals.
- Output, impact, and activity dimensions lack underlying data and are left unscored; the record in scope covers only two 2026 preprints.
- Evolve verdicts reflect review of the two cataloged preprints, not the researcher's full publication record.